Search the Newsreel

AWSX der Telegram-Trader.de: Gilead Sciences überzeugt mit starkem Wachstum - Prognose Kerngeschäft steigt

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Gilead Sciences reported a $10.5 billion loss in the second quarter, primarily due to new research-and-development expenses from recent acquisitions. Despite this loss, the biopharmaceutical company saw revenue growth, largely driven by strong sales of its HIV products. Gilead also lowered its full-year forecast …

Gilead Revenue Jumps as Acquisitions Lead to Adjusted Loss

Gilead Sciences reported increased revenue in its second quarter, primarily driven by its strong HIV drug portfolio. Despite the revenue growth, the company posted an adjusted loss due to significant dealmaking costs associated with recent acquisitions. This indicates that while core business performance is …

Gilead Sciences Q2 2026: Revenue $7.8B, Product Sales $7.6B, EPS (GAAP) $(8.45)

Gilead Sciences reported Q2 2026 results with total revenues of $7.8 billion and product sales of $7.6 billion, marking a 10% year-over-year increase in product sales excluding Veklury. The company recorded GAAP diluted loss per share of $(8.45) due to significant acquired IPR&D expenses. …

Gilead second-quarter sales rise 8%, beating Wall Street estimates

By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss ‌due to costs related to a series of acquisitions. The company's overall revenue …

Gilead Sales Beat Expectations on Strong HIV Prevention Growth

Gilead Sciences Inc. reported second-quarter sales that exceeded expectations, driven by strong performance in its HIV prevention and treatment drugs. The company's revenue increased by 10% to $7.8 billion, surpassing Wall Street's projection of $7.4 billion. Notably, quarterly sales for HIV prevention medicines surpassed …

Gilead Sciences Secures Landmark California Supreme Court Victory, Eliminating Nearly 23,000 "Duty to Innovate" Cases

Gilead Sciences won a significant victory in the California Supreme Court, which ruled that drug manufacturers do not owe a "duty to innovate" or develop alternative drugs for nondefective products. This decision dismisses nearly 23,000 consolidated cases against Gilead, preventing a new form of …

Gilead Sciences Stock (GILD) Opinions on Earnings Report

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here's what to expect. Gilead Sciences beat analysts' revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% …

Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.

Gilead Sciences, Inc. has repurchased 2,693,030 shares for $355 million between April 1, 2026, and June 30, 2026, as part of its buyback plan announced on February 25, 2020. This brings the total repurchased shares to 51,569,874, representing 4.14% of its equity, for a …

Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B

Gilead Sciences, Inc. announced its Q2 2026 revenue of $7.80 billion, surpassing FactSet's estimate of $7.40 billion. Despite this revenue beat, the company swung to an adjusted loss of $6.75 per share, compared to an estimated loss of $7.26 per share, primarily due to …

Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Is Ermenegildo Zegna (ZGN) Fully Valued As Higher Revenue Draws Investors Back?

Gilead's $8.45 Q2 per-share loss reflects $11.2B in acquisition research costs

Does Gildan (TSX:GIL) Balancing Losses, Cautious Guidance and Dividends Reveal Its True Strategy?

Gildan Activewear Inc. recently reported a net loss of US$49.95 million in Q2 2026 despite rising sales, leading to updated full-year revenue guidance at the lower end of expectations. However, management projects a Q3 sales rebound with US$1.65 billion from continuing operations and confirmed …

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here's what to expect. Gilead Sciences beat analysts' revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% …

California Supreme Court Rules for Gilead, Says Drugmakers Don’t Have ‘Duty to Innovate’

The California Supreme Court ruled in favor of Gilead Sciences, stating that drug manufacturers of safe drugs do not have a "duty to innovate" and develop potentially safer alternatives. This decision dismisses negligence claims from 24,000 patients using an HIV drug from Gilead, reversing …

Can Gildan (GIL) Run Higher on Rising Earnings Estimates?

Gildan Activewear (GIL) shows potential for stock appreciation due to significant upward revisions in its earnings estimates by analysts. The company's strong Zacks Rank #2 (Buy) and positive revisions for both current-quarter and full-year EPS suggest continued growth, making it an attractive option for …

Opinion | Gilead Beats the Plaintiff Bar

The California Supreme Court rejected a lawsuit against Gilead Sciences, providing a rare win for businesses against expansive liability theories. The suit, brought by 24,000 HIV patients, claimed Gilead delayed a new drug launch to maximize profits from an existing medicine. The court's decision …

California Supreme Court sides with Gilead in ‘duty’ to innovate case

The California Supreme Court has ruled in favor of Gilead Sciences in a significant case concerning the company's development of HIV medications. The 6-1 decision overturned a previous appeals court ruling, which had suggested Gilead could be held liable for allegedly slow-walking the development …

Gilead wins California Supreme Court decision that it calls 'a victory for all' drug developers

Gilead Sciences Inc. has won a significant case at the California Supreme Court concerning its best-selling HIV drugs. The company views this decision as a victory not only for itself but also for all drug developers working on new and improved medical treatments. This …

California's highest court rules for Gilead in 'duty to innovate' case

California's highest court has sided with Gilead Sciences in a landmark "duty to innovate" case, dismissing negligence claims from 24,000 HIV patients. The court ruled that drug manufacturers are not liable for failing to make a different, potentially safer drug available sooner, even if …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Gildan Activewear Inc. (GIL) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gildan Activewear Inc. (NYSE: GIL) following a report by Jehoshaphat Research. The report, published on June 16, 2026, alleges that Gildan has been "stuffing the channel" and using "financial engineering" …

How Much Upside is Left in Gildan (GIL)? Wall Street Analysts Think 43.12%

Shares of Gildan Activewear (GIL) have gained 7.5% over the past four weeks to close the last trading session at $55.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. …

TD Cowen Maintains Ermenegildo Zegna NV(ZGN.US) With Buy Rating, Raises Target Price to $17

TD Cowen has reaffirmed its Buy rating on Ermenegildo Zegna NV (ZGN.US) and increased its price target to $17. This indicates a positive outlook from the analyst firm regarding the company's future performance and stock value.

Gilead Sciences, Inc. (GILD) Stock Analysis: Solid Growth With A 20.69% Upside Potential

GILDAN ACTIVEWEAR INC : SCOTIABANK RAISES TARGET PRICE TO $67 FROM $65

Scotiabank has increased its target price for GILDAN ACTIVEWEAR INC shares from $65 to $67. This adjustment reflects an updated outlook from the financial institution regarding the company's valuation.

Gildan Activewear Number of Employees 2026 | Employee Count & Headcount Data

Gildan Activewear (GIL) reported approximately 79,523 employees worldwide as of March 2026, marking a 7.1% decline since 2023. Despite this, the company is actively hiring, with 662 active job postings in 2026, a 13.0% increase from the previous year. The workforce is primarily located …

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences, Inc. (GILD) has seen its stock outperform the broader market, driven by FDA approval for its breast cancer drug Trodelvy®. Analysts maintain a "Strong Buy" consensus rating for GILD, with an average price target indicating a significant upside. Despite an expected EPS …

Gildan Activewear, Inc. $GIL Stock Position Lessened by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its stake in Gildan Activewear (NYSE:GIL) by 11.3% in the first quarter, selling 52,733 shares while retaining 414,183 shares valued at $23 million. Despite this, other major institutions like Vanguard and Mackenzie Financial increased their holdings, contributing to …

Gildan Activewear (TSX:GIL) Stock Faces Valuation Heat After Earnings Rebound

Enterprise value to revenue forward of Gildan Activewear Inc. – TSX:GIL

The article discusses the enterprise value to revenue forward for Gildan Activewear Inc. (TSX:GIL). It presents financial information for the company, indicating that the market is currently closed with no trades. The content seems to be a financial data point from TradingView, focusing on …

Gildan Activewear, Inc. (GIL) Stock Forecasts

Gildan Activewear Inc. (TSX:GIL) Climbs on Strong Earnings Momentum, Upgraded Outlook, and Growing Investor Confidence

Gildan Earnings: Mixed Results, but Hanesbrands Integration Progressing; Shares Very Undervalued

Gildan’s Low-Cost Production Provides Advantages in Both Printwear and Apparel Basics Sold at Retail

Gildan (GIL) maintains a narrow economic moat rating from Morningstar due to its cost advantage derived from an efficient, vertically integrated supply chain. This allows the company to excel in the T-shirt and fleece production and distribution, especially in the US printwear market. Despite …

Gildan Activewear, Inc. $GIL Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Gildan Activewear, Inc. (NYSE:GIL) by 72.8% in the first quarter, selling 145,770 shares. Despite this, institutional investors collectively own 82.83% of the company. Gildan reported strong Q2 earnings, exceeding analyst expectations, and announced …